Histone deacetylase inhibitors as new cancer drugs Journal Article


Authors: Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A.
Article Title: Histone deacetylase inhibitors as new cancer drugs
Abstract: Histone deacetylase inhibitors are potent inducers of growth arrest, differentiation, or apoptotic cell death in a variety of transformed cells in culture and in tumor bearing animals. Histone deacetylases and the family of histone acetyl transferases are involved in determining the acetylation of histones, which play a role in regulation of gene expression. Radiograph crystallographic studies reveal that the histone deacetylase inhibitors, suberoylanilide hydroxamic acid and trichostatin A, fit into the catalytic site of histone deacetylase, which has a tubular structure with a zinc atom at its base. The hydroxamic acid moiety of the inhibitor binds to the zinc. Histone deacetylase inhibitors cause acetylated histones to accumulate in both tumor and peripheral circulating mononuclear cells. Accumulation of acetylated histones has been used as a marker of the biologic activity of the agents. Hydroxamic acid-based histone deacetylase inhibitors limit tumor cell growth in animals with little or no toxicity. These compounds act selectively on genes, altering the transcription of only approximately 2% of expressed genes in cultured tumor cells. A number of proteins other than histones are substrates for histone deacetylases. The role that these other targets play in histone deacetylase inducement of cell growth arrest, differentiation, or apoptotic cell death is not known. This review summarizes the characteristics of a variety of inhibitors of histone deacetylases and their effects on transformed cells in culture and tumor growth in animal models. Several structurally different histone deacetylase inhibitors are in phase I or II clinical trials in patients with cancers. © 2001 Lippincott Williams & Wilkins, Inc.
Keywords: unclassified drug; histone deacetylase inhibitor; review; cancer growth; neoplasms; animals; cell death; cell cycle; apoptosis; enzyme inhibition; gene expression; cell growth; tumor markers, biological; genetic transcription; cell differentiation; antineoplastic activity; tumor cells, cultured; gene expression regulation, neoplastic; mononuclear cell; enzyme inhibitors; cell transformation; vorinostat; disease models, animal; zinc; x ray crystallography; histones; histone deacetylases; trichostatin a; acetylation; mitosis inhibition; cancer; humans; human; priority journal
Journal Title: Current Opinion in Oncology
Volume: 13
Issue: 6
ISSN: 1040-8746
Publisher: Lippincott Williams & Wilkins  
Date Published: 2001-11-01
Start Page: 477
End Page: 483
Language: English
DOI: 10.1097/00001622-200111000-00010
PUBMED: 11673688
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 21 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Victoria M Richon
    91 Richon
  2. Paul Marks
    186 Marks
  3. Richard Rifkind
    118 Rifkind
Related MSK Work